| Original language | English (US) |
|---|---|
| Pages (from-to) | 96 |
| Number of pages | 1 |
| Journal | New England Journal of Medicine |
| Volume | 378 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 4 2018 |
Bibliographical note
Funding Information:Dr. Johnson reports receiving research grants from Allergan, Merck, Tetraphase Pharmaceuticals, and the Medicines Company, receiving consulting fees from Crucell (a subsidiary of Janssen) and ICET, and holding patent applications for tests to detect Escherichia coli strains. No other potential conflict of interest relevant to this letter was reported.